Physician

Infectious Disease

Dr. Jeffrey P. Nadler, MD

Dr. Jeffrey P. Nadler is an expert in the field of Infectious Disease. Jeffrey Nadler is a published doctor. He has 27 publications published. The most current publication "Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS."

Publications

Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India.
New HIV Drugs in Development, 2005.
Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort.
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected pa...
Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
Predicting death from HIV/AIDS: a case-control study from Florida public HIV/AIDS clinics.
Daily dosing of highly active antiretroviral therapy.
Fosamprenavir: a new PI option. Interview by Craig Sterritt.
Management of coinfection with human immunodeficiency virus and human T-cell lymphotropic virus type I.
Multiple sclerosis and hepatitis B vaccination.
Case report: Yersinia enterocolitica necrotizing pneumonia in an immunocompromised patient.
Herpesvirus disease: an update.
Maraviroc for previously treated patients with R5 HIV-1 infection.
New anti-HIV protease inhibitors provide more treatment options.
Primary care management of human immunodeficiency virus infection.
Why didn't I go to Durban?
A randomized trial of interferon alpha therapy for HIV type 1 infection.
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.
Infections in HIV-infected patients with malignancy.
Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS.
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.
Early initiation of antiretroviral therapy for infection with human immunodeficiency virus: considerations in 1996.
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

Schools

New York Medical College

Doctors Specialties

Infectious Disease Medicine
Infectious Disease

Accepted Insurances

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Netanya S. Utay, MD This Doctor is OpenDoctor Recommended.
	Dr. Helene F. Rosenberg, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Beverly F. Hall, MD This Doctor is OpenDoctor Recommended.
	Dr. Dale N. Lawrence, MD This Doctor is OpenDoctor Recommended.
	Dr. Tyler E. Warkentien, MD This Doctor is OpenDoctor Recommended.
	Dr. John R. Mascola, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Anuradha Ganesan, MD This Doctor is OpenDoctor Recommended.
	Dr. Gregory A. Deye, MD This Doctor is OpenDoctor Recommended.
	Dr. Janine R. Danko, MD This Doctor is OpenDoctor Recommended.
	Dr. Christa S. Zerbe, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard A. Koup, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Barney S. Graham, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Cynthia L. Fowler, MD This Doctor is OpenDoctor Recommended.
	Dr. Yingda L. Xie, MD This Doctor is OpenDoctor Recommended.
	Dr. David K. Byers, MD